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Abstract 
Background: Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sus‑
tained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients 
live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 
appears to be involved in hepatitis C virus replication.
Methods: We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and 
clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate 
analysis were used in the statistical analysis.
Results: Baseline serum vitamin B12 levels were found to be positively associated with serum transaminase activi‑
ties (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable 
interferon‑λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with 
rapid virological response (p = 0.001). Patients with baseline serum vitamin B12 levels below a cut‑off value of 
570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3–41.9, p < 0.0001] 
compared to patients above the cut‑off value. By combining serum vitamin B12 levels and IFNL3/IFNL4 rs12979860 
genotypes, patients with baseline serum vitamin B12 levels below the cut‑off value of 570 ng/L and IFNL3/IFNL4 
rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9–293, p < 0.0001) compared to 
patients above the cut‑off value and non‑CC‑genotypes.
Conclusion: Our data suggest baseline serum vitamin B12 levels as useful noninvasive marker for characterizing CHC 
patients. They might further help to identify responders to a standard treatment.
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Background
Patients with chronic hepatitis C virus (HCV) infection 
are at risk for progressive hepatic fibrosis, cirrhosis, por-
tal hypertension, liver failure and hepatocellular carci-
noma [1–4]. For the past decade, therapy with pegylated 
interferon-α (Peg-IFN-α) and ribavirin (RBV) yielded 
sustained virological response (SVR) rates of 40–50% 
among treatment naïve CHC patients with HCV geno-
type 1 infection [5, 6]. For those patients who did not 
achieve a SVR, retreatment options were limited to a 
re-exposure to the same medications, maybe modified 
in dose or duration. These retreatment strategies were 
accompanied by clinically significant morbidity (i.e. 
more pronounced side effects) and generally had a lower 
chance of resulting in a successful outcome [7, 8]. The 
recent approval of direct acting antiviral agents (DAAs) 
has inaugurated a new era in the treatment of CHC 
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patients. These agents have raised the rates of SVR above 
90% [9–16].
However, these clinical trials were performed in 
highly selected, triaged patients and the cost of anti-
viral therapy i.e. is only for sofosbuvir approximately 
60,000 € [17]. This is especially relevant in view of 
most of CHC patients living in developing countries. 
Antiviral treatments consisting of sofosbuvir, ledipas-
vir, daclatasvir or simeprevir are not necessarily avail-
able in these countries yet. Thus, it is important to 
identify patients who do have a fair chance to respond 
to standard combination therapy, to avoid unneces-
sarily inducing detrimental side effects and to offer a 
treatment option, which is affordable for most of the 
patients. Several studies to date have aimed to iden-
tify accurate and sensitive predictors of treatment 
response. Besides HCV genotype, several other factors 
related to the virus [e.g. viral load at treatment initia-
tion or rapid virological response (RVR)] and host (e.g. 
race, age, body weight, insulin resistance, serum lipids, 
fibrosis stage, serum ferritin concentration and genetic 
variations in the IFNL3/4 genes) have been shown to 
determine treatment-induced SVR in CHC patients 
[18–24].
HCV is a positive-sense, single-strand RNA virus that 
possesses an internal ribosomal entry site (IRES) at the 
5′ terminus of its genome [25]. The IRES element is a 
complex RNA structure containing distinct domains 
which specifically interact with the ribosomal subunits 
and positions them directly over the initiation codon 
[26]. HCV IRES-mediated translation initiation is part 
of the viral replication mechanism and, given its speci-
ficity and sensitivity to minor structural changes, it is 
considered one of the targets for antiviral strategies. It 
has been shown in an in vitro system that vitamin B12 
inhibits HCV IRES-dependent translation, probably by 
directly interacting with HCV IRES RNA [27, 28]. At 
the same time, vitamin B12 appears to be biologically 
significant for HCV replication, as high serum vita-
min B12 levels were shown to be associated with high 
serum HCV-RNA levels in CHC patients [28]. A study 
by Rosenberg et al. [29] suggested high serum vitamin 
B12 levels to be favorable for achieving an end-of-treat-
ment response in CHC patients. Accordingly, Rocco 
et al. [30] showed in an open-label pilot study that the 
addition of vitamin B12 to standard-of-care increases 
clearance of infection rates in treatment naïve CHC 
patients.
The aim of this study was to assess the relationship 
between serum vitamin B12 levels and clinical, histologi-
cal features of CHC and to analyze its capacity as a pre-
dictor for sustained virus clearance upon a combination 
therapy with Peg-IFN-α and RBV.
Methods
Patients
A total of 116 CHC genotype 1 infected patients were 
included in this study and had their records reviewed. All 
116 patients were from Germany and of Caucasian origin. 
CHC infection was defined by the presence of HCV-RNA 
in the blood for at least 6 months. Liver biopsy specimens 
were processed using standard techniques and evaluated 
for stage of fibrosis and grade of activity according to the 
established criteria [31]. All 116 patients were treated 
with dual antiviral therapy consisting of Peg-IFN-α and 
RBV and followed up at the Department of Gastroenter-
ology and Endocrinology, University Medical Center of 
Goettingen, Germany. Patients with an active hepatitis B 
virus or human immunodeficiency virus infection, those 
with continued alcohol abuse or those who were receiv-
ing immunosuppressive medications were excluded. 
Increased serum levels of vitamin B12 can be seen in mye-
loproliferative disorders such as chronic myelogenous 
leucemia or primary polycythaemia, acute fulminant 
hepatitis, hypereosinophilic syndrome and sometimes in 
renal failure [32]. None of the patients included into the 
present study had a diagnosis of any of these conditions. 
All patients gave written informed consent to participate 
in the study in accordance with the ethical guidelines of 
the 1975 Declaration of Helsinki. The study was approved 
by the ethics committee of the University Medical Center 
(initial approval number 4/8/93 with subsequent amend-
ments). Patients with CHC were treated either with 
Peg-IFN-α2b at a dose of 1.5 µg/kg body weight in com-
bination with weight-based ribavirin (800–1,400 mg per 
day) or 180 µg Peg-IFN-α2a in combination with weight-
based ribavirin (1,000 or 1,200  mg per day). Depending 
upon their individual tolerance and response parameters, 
both the dose and duration of treatment were adjusted. 
Serum HCV-RNA levels were monitored monthly. A 
rapid virologic response (RVR was defined as the elimi-
nation of viral RNA to a level below the limit of detect-
ability (<50 copies/ml) during the first 4 weeks of therapy. 
Successful treatment was defined as a SVR, defined as the 
lack of detectability of HCV-RNA 6 months after cessa-
tion of therapy. The enzymatic activities of serum aspar-
tate aminotransferase (AST), γ-glutamyl-transferase 
(γ-GT) and alanine aminotransferase (ALT) as well as 
baseline serum vitamin B12 levels were determined by 
utilizing the automated systems of the Central Labora-
tory of the Department of Clinical Chemistry at Univer-
sity Medical Center Goettingen.
Isolation of genomic DNA and IFNL3/IFNL4 rs12979860 
single nucleotide polymorphism (SNP) genotyping
These procedures were performed as described previ-
ously [33].
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Detection and determination of serum HCV‑specific RNA 
and HCV genotype
Serum HCV-specific RNA was determined utilizing a 
nested RT-PCR assay and subsequent determination of 
the HCV genotypes. These procedures were performed 
as described previously [33].
Statistical analyses
Associations between serum vitamin B12 levels with con-
tinuous (i.e., HCV viral load and serum ALT levels) and 
dichotomic variables (e.g., SVR versus no SVR, stage of 
liver fibrosis, hepatitis activity, and degree of steatosis) 
were assessed in logistic regression models, respectively. 
After univariate analysis, multivariate analysis was per-
formed for significant associations. Multivariate analy-
sis were obtained by using backward selection, with a 
p value >0.10 for removal from the model. Continuous 
and categorical variables were compared between those 
with a SVR and those without utilizing Wilcoxon Mann–
Whitney, χ2 and Fisher’s exact tests. As our observational 
data regarding serum vitamin B12 levels were skewed we 
have decided to use quartiles, interquartile range (IQR) 
and Spearman’s correlations between continuous vari-
ables in our analysis. A p value of <0.05 was considered 
to be statistically significant. All statistical analyses were 
performed using the statistic program R cited at http://
www.r-project.org and logistic regression calculators 
cited at http://statpages.org/logistic.html. Formulas with 
risk scores that best predicted the study’s other end-
points (marked fibrosis and cirrhosis) were constructed 
by entering different sets of independent variables into 
the regression model. Hardy–Weinberg equilibrium 
calculations cited at http://ihg.gsf.de/cgi-bin/hw/hwa1.
pl were used as well. The receiver operating characteris-
tics (ROC) curve and the area under the receiver oper-
ating characteristics (AUROC) were calculated by using 
GraphPad Prism 5.
Results
A total of 116 CHC genotype 1 infected, treatment-naïve 
patients were included in this analysis (Table 1). 41% were 
female, their median age was 51  years (range 22–80). 
Patients had either HCV genosubtype 1a (29%) or 1b 
(67%) or had coinfection with both genosubtypes 1a + b 
(4%). The baseline enzymatic activities of AST, γ-GT and 
ALT as well as baseline serum vitamin B12 and HCV-RNA 
levels of all patients are presented in Table 1. A baseline 
histological evaluation of a liver biopsy was available in 
all patients. 32% (37/116) of the patients showed mod-
erate/severe hepatitis activity. 23% (27/116) had severe 
fibrosis or cirrhosis. 49% (57/115) of the patients had 
steatosis above 5%. IFNL3/IFNL4 rs12979860 genotyping 
revealed a genotype distribution of 44:54:14 (CC:CT:TT) 
with a minor allele frequency of 0.37. Genotype distribu-
tion met the Hardy–Weinberg equilibrium (p = 0.64).
Quartile of baseline serum vitamin B12 levels with regard 
to treatment response, laboratory, histological and IFNL3/
IFNL4 rs12979860 genotypes
The median value of baseline serum vitamin B12 levels was 
488 ng/L (IQR, 339–727). No patient had baseline serum 
vitamin B12 levels below the lower normal limit. Median 
baseline serum vitamin B12 levels were 333  ng/L in SVR 
patients and 616 ng/L in non-responders (p < 0.0001) (Fig-
ure 1). Table 2 displays the associations between baseline 
serum vitamin B12 levels and several clinical and demo-
graphic variables, categorized according to the quartiles 
of vitamin B12. Low baseline serum vitamin B12 levels were 
significantly associated with RVR (p  =  0.001) and SVR 
(p  <  0.001). Low baseline serum vitamin B12 levels were 
also associated with low serum activity of AST (p = 0.002), 
ALT (p = 0.04), lower stages of fibrosis (p = 0.0001) and 
the favorable allele C of the IFNL3/IFNL4 rs12979860 SNP 
(p  =  0.04). Moreover, baseline serum vitamin B12 levels 
were positively and significantly correlated with baseline 
serum HCV-RNA load (p < 0.0001) (Figure 2).
Table 1 Patient baseline characteristics
Laboratory data are presented as mean and interquartile (IQR); number of cases 
are given in total and as a percentage; Baseline serum vitamin B12 levels were 
available for 107 patients.
Male/female sex n (%) 68/48 (59%/41%)
Age [median (range)] 51 (22–80)
HCV subtype n (%)1a/1b/1a + b 34/77/5 (29%/67%/4%)
HCV‑RNA level [median (IQR)] copies/mL 1.8 × 106 (4.5 × 105–6.2 × 106)
AST [median (IQR)] U/L 44 (32–73)
ALT [median (IQR)] U/L 51 (32–93)
γ‑GT [median (IQR)] U/L 50 (28–100)
Vitamin B12 [median (IQR)] ng/L 488 (339–727)
Hepatitis activity n (%)
 Mild 79 (68%)
 Moderate/severe 37 (32%)
Fibrosis n (%)
 Absent/mild/moderate 89 (77%)
 Severe/cirrhosis 27 (23%)
Steatosis n (%)
 0–5% 58 (50%)
 6–100% 57 (49%)
 Missing 1 (1%)
IFNL3/IFNL4 rs12979860 n (%)
 CC 44 (38%)
 CT 54 (47%)
 TT 14 (12%)
 Missing 4 (3%)
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Treatment response with regard to baseline serum vitamin 
B12 levels, histological features, baseline and on‑treatment 
HCV‑RNA levels and IFNL3/IFNL4 rs12979860 genotypes
The overall SVR rate of CHC genotype 1 patients was 
41%. Factors which were found to be associated to SVR 
in univariate analysis included low baseline serum vita-
min B12 levels (p < 0.001), low stage of fibrosis (p = 0.01) 
and low degree of steatosis (p = 0.02), low baseline HCV-
RNA levels (p  <  0.001), RVR (p  <  0.001) and IFNL3/
IFNL4 rs12979860 CC genotype (p =  0.0001) (Table 3). 
A multivariate analysis revealed that all these parameters 
were significantly and independently related to sustained 
virus eradication (Table 3).
A cut-off value for serum vitamin B12 of 570 ng/L has 
been chosen using a ROC analysis with an AUROC of 
0.83 (Figure  3). The sensitivity, specificity and positive 
and negative predictive values (PPV and NPV) of base-
line vitamin B12 level were calculated to amount to 91, 58, 
59 and 90%, respectively (data not shown). Patients with 
baseline serum vitamin B12 levels <570  ng/L achieved a 
SVR rate of 59% (39/66) with an OR of 13.4 (CI 4.3–41.9, 
p < 0.0001) compared to the group of patients with levels 
Figure 1 Association between baseline serum vitamin B12 levels and 
therapeutic outcome. Patients with sustained virological response 
(SVR) had lower baseline serum vitamin B12 levels than patients with 
non sustained virological response (NVR).
Table 2 Quartile of baseline serum vitamin B12 levels with regard to host and viral factors and treatment response
Characteristics <340 (n = 27) 340–488 (n = 27) 488–727 (n = 26) >727 (n = 27) P value
Male sex n (%) 19 (70%) 20 (74%) 13 (50%) 13 (48%) 0.29
Age [median (range)] 47 (23–77) 53 (22–70) 51 (32–73) 51 (23–71) 0.74
HCV subtype n (%)
 1a 8 (29%) 12 (44%) 7 (27%) 6 (22%) 0.55
 1b 18 (67%) 15 (56%) 18 (69%) 19 (70%)
 1a + b 1 (4%) 0 1 (4%) 2 (8%)
RVR n (%) 19 (70%) 12 (44%) 9 (35%) 5 (19%) 0.001
SVR n (%) 22 (81%) 12 (44%) 7 (27%) 2 (7%) <0.001
AST [median (IQR)] U/L 39 (30–54) 42 (32–51) 45 (36–77) 73 (53–121) 0.002
ALT [median (IQR)] U/L 46 (24–94) 44 (27–64) 55 (36–85) 66 (49–150) 0.04
γ‑GT [median (IQR)] U/L 38 (28–87) 52 (24–103) 63 (41–136) 68 (28–142) 0.12
Hepatitis activity n (%)
 Mild 21 (78%) 18 (67%) 19 (73%) 15 (56%) 0.58
 Moderate/severe 6 (22%) 9 (33%) 7 (27%) 12 (44%)
Fibrosis n (%)
 Absent/mild/moderate 26 (96%) 22 (81%) 22 (85%) 11 (41%) 0.0001
 Severe/cirrhosis 1 (4%) 5 (19%) 4 (15%) 16 (59%)
Steatosis
 0–5% 21 (78%) 19 (70%) 19 (73%) 15 (56%) 0.26
 6–100% 6 (22%) 7 (26%) 7 (27%) 12 (44%)
 Missing 0 1 (4%) 0 0
IFNL3/IFNL4 rs12979860 n (%)
 CC 16 (59%) 11 (41%) 5 (19%) 9 (33%) 0.04
 CT 8 (30%) 15 (55%) 15 (58%) 12 (44%) 8 (30%)
 TT 2 (7%) 1 (4%) 5 (19%) 5 (19%) 2 (7%)
 Missing 1 (4%) 0 1 (4%) 1 (4%) 1 (4%)
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above 570  ng/L who achieved only a SVR rate of 10% 
(4/41) (Figure  4). Patients with baseline serum vitamin 
B12 levels below the cut-off value of 570 ng/L and IFNL3/
IFNL4 rs12979860 CC genotype, however, achieved a 
SVR rate of 80% (24/30) with an OR of 54 (CI 9.9–293, 
p  <  0.0001) when compared to patients above the cut-
off value carrying the non-CC IFNL3/IFNL4 rs12979860 
allele (Figure 5).
Discussion
The therapy of CHC patients is currently undergoing a 
dramatic upheaval, especially with the introduction of the 
new DAAs such as Sofosbuvir, Simeprevir, Daclatasvir or 
Ledipasvir. With these new therapy regimens, patients 
achieve SVR rates above 90% [14–16, 34]. For these 
patients, there is not necessarily a need for new predic-
tors. However, considering the situation worldwide, it 
becomes clear that only a fraction of CHC patients would 
have access to such an expensive therapy. The majority 
of patients living in countries with lower health budget 
might be treated with Peg-IFN-α and RBV in the next 
years, which is less effective and may have serious side 
effects. To optimize such an antiviral therapy regimen, 
more factors have to be evaluated and validated to pro-
tect patients from severe adverse events or discontinua-
tion of therapy and to predict the individual probability 
of SVR with highest possible certainty.
Figure 2 Spearman correlation between baseline serum vitamin 
B12 (ng/L) levels and HCV‑RNA (copies/mL). This figure is the plot of 
the log of the HCV viral load as a function of the log of total serum 
vitamin B12 level.
Table 3 Uni- and multivariate analysis of factors associated with treatment response
RVR rapid virological response.
Characteristics Univariate analysis Multivariate analysis
P value P value
Male sex n (%) 68 (59%) 0.07 0.19
Age [median (range)] 51 (22–80) 0.28
RVR n (%) 40 (82%) <0.001 <0.001
Vitamin B12 [median (IQR)] ng/L 488 (339–727) <0.001 <0.001
HCV‑RNA level [median (IQR)] copies/mL 1.8 × 106 (4.5 × 105–6.2 × 106) <0.001 <0.05
IFNL3/IFNL4 rs12979860 CC n (%) 28 (64%) 0.0001 <0.001
Hepatitis activity n (%)
 Mild 79 (68%) 0.70
Fibrosis n (%)
 Absent/mild/moderate 89 (77%) 0.01 <0.05
Steatosis n (%)
 0–5% 58 (50%) 0.02 0.01
Figure 3 Receiver operating characteristics (ROC) Curve of baseline 
serum vitamin B12 levels. This ROC curve shows the relation between 
sensitivity and specificity regarding the baseline serum vitamin B12 
levels and HCV therapy response.
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There are a number of demographical, laboratory, his-
tological, genetical and virological predictors for the 
treatment of CHC patients with Peg-IFN-α and RBV 
[21, 22, 35, 36] or with Peg-IFN-α, RBV and one of the 
first-generation protease inhibitors [37]. These factors 
could predict very accurately an individual’s chance to 
achieve a SVR. By combining independent predictors, a 
better prediction can be made. One example for this is 
the combination of IFNL3/IFNL4 rs12979860 genotypes 
and the ratio of γ-GT and ALT serum activities (γ-GT/
ALT) [22, 38]. Simple and quickly determinable labora-
tory parameters may help physicians in countries with 
lower health budget to identify CHC patients who would 
achieve a high SVR rate upon an antiviral treatment with 
Peg-IFN-α and RBV.
There is some evidence that vitamin B12 inhibits dose-
dependently the HCV IRES-dependent translation [28, 
39]. On the other hand, high levels of serum vitamin B12 
are statistically correlated with high viral load [28]. Vita-
min B12 thus might have opposing effects on HCV trans-
lation and replication.
According to Lott et al. [28] HCV may have evolved to 
use high vitamin B12 levels in the hepatocytes for obtain-
ing maximum replications values.
Several liver diseases such as hepatitis, cirrhosis, hepa-
tocellular carcinoma and metastasis, may be accom-
panied by relative vitamin B12 deficiency secondary to 
impaired liver storage. This consequents to the increased 
release during hepatic cytolysis and/or decreased clear-
ance by the affected liver [40]. Therefore, in this situation 
and given the natural role of vitamin B12 in the regulation 
of the HCV replication cycle [28], it is conceivable that 
administration of vitamin B12 might improve the rates of 
virological response to antiviral therapy in HCV carriers.
This study confirms the results of Lott et al. [28] with 
regard to a positive relationship between serum vitamin 
B12 levels and serum viral load. Furthermore, it also could 
be shown that serum vitamin B12 levels were associated 
with the stage of fibrosis in CHC-genotype-1-infected 
Figure 4 Association of serum vitamin B12 levels with a 570 ng/L 
cut‑off value with regard to SVR. This box plot shows the relation‑
ship between baseline serum vitamin B12 levels below or above the 
cut‑off value of 570 ng/L and the sustained virological response (SVR) 
rate. The numbers in brackets represent: number of patients with SVR/
total number of patients.
Figure 5 Association of IFNL3/IFNL4 rs12979860 genotypes and baseline serum vitamin B12 levels with a cut‑off value of 570 ng/L with regard to 
SVR. This Box plot shows the SVR rates for antiviral therapy when both IFNL3/IFNL4 rs12979860 and baseline serum vitamin B12 levels below or above 
the cut‑off value of 570 ng/L were considered. The numbers in brackets represent: number of patients with SVR/total number of patients in that 
group.
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patients. In this context, the content of vitamin B12 con-
centration in the liver would be interesting, and possibly 
reduced. Moreover, this study demonstrated that vitamin 
B12 is associated with RVR and SVR and thus might be 
a further simple and quickly determinable predictor for 
antiviral treatment response to a regimen consisting Peg-
IFN-α and RBV.
In contrast to these results, Rosenberg et  al. [29] 
showed that higher baseline serum vitamin B12 levels 
were correlated with End-of-Treatment Response but 
not with SVR. However, the study of Rosenberg et al. [29] 
included 45 CHC genotype-1-infected patients only and 
therefore it may be statistically underpowered.
Recently, Rocco et al. [30] conducted the first prospec-
tive study, which showed that supplementation of vitamin 
B12 to Peg-IFN-α and RBV significantly improved the SVR 
rate compared to a control group without supplementa-
tion of vitamin B12. One reason for the better results of 
patients treated with Peg-IFN-α, RBV and vitamin B12 
may be that vitamin B12 inhibits HCV IRES-dependent 
translation, probably by directly interacting with HCV 
IRES RNA [27, 28]. Another reason might be a modulat-
ing effect of vitamin B12 on the immune system [41].
The main limitation of this study is the observational 
nature regarding the analyzed data which cannot offer 
information about the molecular pathway how serum 
vitamin B12 predicts SVR.
Conclusion
Baseline serum vitamin B12 levels were found to associ-
ate with the stage of fibrosis in CHC patients with HCV 
genotype 1 infection. Serum vitamin B12 levels were also 
found to independently predict sustained viral clearance 
to a combination therapy consisting of Peg-IFN-α and 
RBV. By combining the predictive value of IFNL3/IFNL4 
rs12979860 genotype and serum vitamin B12 levels, dis-
crimination of responding and non-responding individu-
als can reach an OR of 54 at best. The determination of 
serum vitamin B12 levels thus may be useful as a nonin-
vasive surrogate marker for the stage of fibrosis on one 
hand and may also help to predict responsiveness to Peg-
IFN-α and RBV therapy on the other.
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